Here, we treated ovarian cancer cell lines exhibiting varying mRNA levels of SYCP2 with three FDA-approved TKIs targeting ABL1—dasatinib, nilotinib, and imatinib. This evidence concerns the gene SYCP2 and ovarian cancer.